People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| GENELUX Corp | — | Biotechnology | Series B | $24.3M | $61.1M | 2023 |
Paul Scigalla at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul Scigalla on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Thomas | 1 | 10 |
| Doug Samuelson | 1 | 2 |
| DENNIS R. FENTON | 1 | 2 |
| JOHN R. THOMAS | 1 | 2 |
| James Tyree | 1 | 2 |
| Mary Mirabelli | 1 | 1 |
| Thomas Zindrick | 1 | 1 |
| CATHERINE R. MACKEY | 1 | 1 |
| Gabe Woodward | 1 | 1 |
| ALBERT H. RODER | 1 | 1 |
| ALADAR A. SZALAY | 1 | 1 |
| JAMES R. TYREE | 1 | 1 |
| RONALD R. SIMUS | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.